Financial statements are reported in EUR. Prices converted from USD at today's exchange rate. Tranches and alerts stay in USD.
LKFT — Lakefront Biotherapeutics NV
€30.81
+€0.05 (+0.15%)
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Market Cap
€2.03B
Forward P/E
-30.3x
52-Week Range
N/A
LKFT Price History
Revenue vs. Net Income
€1.1B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-€271M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
9.3%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
20.0x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
1.2%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
-0.4%
Net buyback · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
